| Code | CSB-RA025141MB9HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to QX-008N, designed to specifically target thymic stromal lymphopoietin (TSLP), a key epithelial cell-derived cytokine that plays a critical role in initiating and maintaining type 2 inflammatory responses. TSLP is primarily expressed at barrier surfaces including the skin, lungs, and gastrointestinal tract, where it activates dendritic cells and triggers downstream Th2-mediated immune cascades. Elevated TSLP expression has been strongly implicated in the pathogenesis of allergic diseases such as atopic dermatitis, asthma, allergic rhinitis, and eosinophilic esophagitis, making it an important therapeutic target for understanding type 2 inflammation.
QX-008N represents an investigational anti-TSLP monoclonal antibody developed for studying TSLP-mediated inflammatory pathways. This biosimilar provides researchers with a valuable tool for investigating TSLP biology, exploring its role in allergic and inflammatory disease mechanisms, and evaluating potential therapeutic interventions targeting type 2 immune responses in preclinical models and translational research settings.
There are currently no reviews for this product.